Expression profile of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: Changes in expression from benign to malignant tumours

Histopathology

Volumn 66, Issue 4, 2015, Pages 529-535

  Wang, Jayson ^a   El Bahrawy, Mona ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Immunohistochemistry; Mucin; Ovary; Tumorigenesis; Tumour

Indexed keywords

MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6; MUC2 PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; MUC6 PROTEIN, HUMAN;

ARTICLE; BENIGN TUMOR; CANCER GROWTH; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; TUMOR DIFFERENTIATION; COLLOID CARCINOMA; FACTUAL DATABASE; METABOLISM; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; DATABASES, FACTUAL; FEMALE; HUMANS; MUCIN 5AC; MUCIN-1; MUCIN-2; MUCIN-6; OVARIAN NEOPLASMS;

EID: 84922794594     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12578     Document Type: Article

References (19)

1. Chauhan SC, Kumar D, Jaggi M. Mucins in ovarian cancer diagnosis and therapy. J. Ovarian Res. 2009; 2; 21-29.
2. Yonezawa S, Higashi M, Yamada N et al. Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol. Int. 2011; 61; 697-716.
3. Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis and therapy of cancer. BioFactors 2009; 35; 509-527.
4. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am. J. Surg. Pathol. 2003; 27; 985-993.
5. Wang J, El-Bahrawy M. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors. Int. J. Gynecol. Pathol. 2014; 33; 166-175.
6. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum. Pathol. 2000; 31; 672-677.
7. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum. Pathol. 1994; 25; 364-372.
8. Hirabayashi K, Yasuda M, Kajiwara H et al. Alterations in mucin expression in ovarian mucinous tumors: immunohistochemical analysis of MUC2, MUC5AC, MUC6, and CD10 expression. Acta Histochem. Cytochem. 2008; 41; 15-21.
9. Dong Y, Walsh MD, Cummings MC et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J. Pathol. 1997; 183; 311-317.
10. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol. 2002; 32; 525-529.
11. Boman F, Buisine MP, Wacrenier A, Querleu D, Aubert JP, Porchet N. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study. J. Pathol. 2001; 193; 339-344.
12. Chu PG, Chung L, Weiss LM, Lau SK. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am. J. Surg. Pathol. 2011; 35; 1830-1836.
13. Burjonrappa SC, Reddimasu S, Nawaz Z, Gao X, Sharma P, Loggie B. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. Indian J. Cancer 2007; 44; 1-5.
14. Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J. Clin. Pathol. 2003; 56; 378-384.
15. Zheng H, Takahashi H, Nakajima T et al. MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J. Cancer Res. Clin. Oncol. 2006; 132; 817-823.
16. Percinel S, Savas B, Ensari A et al. Mucins in the colorectal neoplastic spectrum with reference to conventional and serrated adenomas. Turk. J. Gastroenterol. 2007; 18; 230-238.
17. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 1996; 63; 298-304.
18. Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 2008; 14; 3060-3069.
19. Oei AL, Moreno M, Verheijen RH et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 2008; 123; 1848-1853.